MALLORY MILLIGAN: Open Payments
NPI 1518656404 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,651 in 96 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $686 · 2025 $1,651
Food & beverage: $1,651
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 20 | $284 |
| Lilly USA, LLC | 18 | $270 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $204 |
| AstraZeneca Pharmaceuticals LP | 4 | $167 |
| ABBVIE INC. | 11 | $146 |
| GlaxoSmithKline, LLC. | 5 | $118 |
| Dexcom, Inc. | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $40 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
Products named: JARDIANCE, MOUNJARO, AIRSUPRA, Ozempic, Rybelsus, TRELEGY ELLIPTA, Dexcom G6 Transmitter, QULIPTA.
Industry payments across TX — which companies pay providers there.
